throbber

`
`
`
`HIGHLIGHTS OF PRESCRIBING INFORMATION
`
`These highlights do not include all the information needed to use
`IMBRUVICA safely and effectively. See full prescribing information for
`
` IMBRUVICA.
`IMBRUVICATM (ibrutinib) capsules, for oral use
`
`Initial U.S. Approval: 2013
`
`----------------------------INDICATIONS AND USAGE---------------------------
`
`IMBRUVICA is a kinase inhibitor indicated for the treatment of patients with
`mantle cell lymphoma (MCL) who have received at least one prior therapy
`(1).
`
`This indication is based on overall response rate. An improvement in survival
`or disease-related symptoms has not been established (14.1).
`-----------------------DOSAGE AND ADMINISTRATION-----------------------
`
`560 mg taken orally once daily (four 140 mg capsules once daily) (2.2).
`
`
`Capsules should be taken orally with a glass of water. Do not open, break, or
`
`
`chew the capsules (2.1).
`
`
`----------------------DOSAGE FORMS AND STRENGTHS---------------------
`Capsule: 140 mg (3)
`
`
`-------------------------------CONTRAINDICATIONS------------------------------
`None
`------------------------WARNINGS AND PRECAUTIONS-----------------------
`• Hemorrhage: Monitor for bleeding (5.1).
`
`
`• Infections: Monitor patients for fever and infections and evaluate promptly
`
`
`(5.2).
`• Myelosuppression: Check complete blood counts monthly (5.3).
`
`
`FULL PRESCRIBING INFORMATION: CONTENTS*
`1
`INDICATIONS AND USAGE
`
`
`2 DOSAGE AND ADMINISTRATION
`
`
`
`2.1 Dosing Guidelines
`
`2.2 Dosage for Mantle Cell Lymphoma
`
`
`2.3 Dose Modifications for Adverse Reactions
`
`
`2.4 Dose Modifications for Use with CYP3A Inhibitors
`2.5 Missed Dose
`3 DOSAGE FORMS AND STRENGTHS
`
`
`4 CONTRAINDICATIONS
`
`
`5 WARNINGS AND PRECAUTIONS
`
`
`5.1 Hemorrhage
`Infections
`5.2
`
`5.3 Myelosuppression
`
`Renal Toxicity
`5.4
`
`
`Second Primary Malignancies
`5.5
`Embryo-Fetal Toxicity
`5.6
`
`6 ADVERSE REACTIONS
`
`
`7 DRUG INTERACTIONS
`
`
`7.1
`CYP3A Inhibitors
`CYP3A Inducers
`7.2
`
`
`
`
`
`
`
`
`Reference ID: 3395788
`
`• Renal Toxicity: Monitor renal function and maintain hydration (5.4).
`
`
`• Second Primary Malignancies: Other malignancies have occurred in
`
`
`patients, including skin cancers, and other carcinomas (5.5).
`
`• Embryo-Fetal Toxicity: Can cause fetal harm. Advise women of the
`
`potential risk to a fetus and to avoid pregnancy while taking the drug (5.6).
`
`------------------------------ADVERSE REACTIONS-------------------------------
`
`The most common adverse reactions (≥20%) in patients with MCL were
`thrombocytopenia, diarrhea, neutropenia, anemia, fatigue, musculoskeletal
`pain, peripheral edema, upper respiratory tract infection, nausea, bruising,
`
`dyspnea, constipation, rash, abdominal pain, vomiting and decreased appetite
`(6).
`
`To report SUSPECTED ADVERSE REACTIONS, contact
`
`Pharmacyclics at 1-877-877-3536 or FDA at 1-800-FDA-1088 or
`
`www.fda.gov/medwatch
`
`-------------------------------DRUG INTERACTIONS------------------------------
`
`CYP3A Inhibitors: Avoid co-administration with strong and moderate CYP3A
`inhibitors. If a moderate CYP3A inhibitor must be used, reduce IMBRUVICA
`
`dose (2.4, 7.1).
`
`CYP3A Inducers: Avoid co-administration with strong CYP3A inducers (7.2).
`
`
`-----------------------USE IN SPECIFIC POPULATIONS------------------------
`
`Hepatic Impairment: Avoid use of IMBRUVICA in patients with baseline
`hepatic impairment (8.7).
`
`
`
`See 17 for PATIENT COUNSELING INFORMATION and FDA
`
`approved patient labeling.
`
`
`
`Revised: 11/2013
`
`
`8 USE IN SPECIFIC POPULATIONS
`
`
`8.1
`Pregnancy
`8.3 Nursing Mothers
`8.4
`Pediatric Use
`8.5 Geriatric Use
`8.6
`Renal Impairment
`8.7 Hepatic Impairment
`8.8
`Females and Males of Reproductive Potential
`11 DESCRIPTION
`
`
`12 CLINICAL PHARMACOLOGY
`
`
`12.1 Mechanism of Action
`
`
`12.2 Pharmacodynamics
`
`12.3 Pharmacokinetics
`
`13 NONCLINICAL TOXICOLOGY
`
`
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`14 CLINICAL STUDIES
`
`
`14.1 Mantle Cell Lymphoma
`
`
`16 HOW SUPPLIED/STORAGE AND HANDLING
`
`
`17 PATIENT COUNSELING INFORMATION
`
`
`
`* Sections or subsections omitted from the full prescribing information are
`
`not listed.
`
`1
`
`
`
`

`

`
`FULL PRESCRIBING INFORMATION
`
`1
`
` INDICATIONS AND USAGE
` IMBRUVICA is indicated for the treatment of patients with mantle cell lymphoma (MCL) who
`
`
`have received at least one prior therapy. This indication is based on overall response rate. An
` improvement in survival or disease-related symptoms has not been established [see Clinical
`
`Studies (14.1)].
`
`
`DOSAGE AND ADMINISTRATION
`2
`
`Dosing Guidelines
`2.1
`
`Administer IMBRUVICA orally once daily at approximately the same time each day. Swallow
`the capsules whole with water. Do not open, break, or chew the capsules.
`
`2.2
`Dosage for Mantle Cell Lymphoma
`The recommended dose of IMBRUVICA for MCL is 560 mg (four 140 mg capsules) orally once
`daily.
`
`
`Dose Modifications for Adverse Reactions
`2.3
`
`Interrupt IMBRUVICA therapy for any Grade 3 or greater non-hematological, Grade 3 or greater
`neutropenia with infection or fever, or Grade 4 hematological toxicities. Once the symptoms of
`the toxicity have resolved to Grade 1 or baseline (recovery), IMBRUVICA therapy may be
`reinitiated at the starting dose. If the toxicity reoccurs, reduce dose by one capsule (140 mg per
`day). A second reduction of dose by 140 mg may be considered as needed. If these toxicities
`persist or recur following two dose reductions, discontinue IMBRUVICA.
`Recommended dose modifications for these toxicities are described below:
`
`Toxicity Occurrence
`
`MCL Dose Modification After Recovery
`Starting Dose = 560 mg
`
`First
`Second
`Third
`Fourth
`
`Restart at 560 mg daily
`Restart at 420 mg daily
`Restart at 280 mg daily
`Discontinue IMBRUVICA
`
`
`2.4
`Dose Modifications for Use with CYP3A Inhibitors
`
`Avoid co-administration with strong or moderate CYP3A inhibitors and consider alternative
`agents with less CYP3A inhibition.
`Concomitant use of strong CYP3A inhibitors which would be taken chronically (e.g., ritonavir,
`indinavir, nelfinavir, saquinavir, boceprevir, telaprevir, nefazodone) is not recommended. For
`short-term use (treatment for 7 days or less) of strong CYP3A inhibitors (e.g., antifungals and
`
`Reference ID: 3395788
`
`2
`
`

`

`
`antibiotics) consider interrupting IMBRUVICA therapy until the CYP3A inhibitor is no longer
`needed [see Drug Interactions (7.1)].
`Reduce IMBRUVICA dose to 140 mg if a moderate CYP3A inhibitor must be used (e.g.,
`fluconazole, darunavir, erythromycin, diltiazem, atazanavir, aprepitant, amprenavir, fosamprevir,
`crizotinib, imatinib, verapamil, grapefruit products and ciprofloxacin) [see Drug Interactions
`(7.1)].
`
`Patients taking concomitant strong or moderate CYP3A inhibitors should be monitored more
`closely for signs of IMBRUVICA toxicity.
`
`2.5 Missed Dose
`If a dose of IMBRUVICA is not taken at the scheduled time, it can be taken as soon as possible
`on the same day with a return to the normal schedule the following day. Extra capsules of
`IMBRUVICA should not be taken to make up for the missed dose.
`
`
`DOSAGE FORMS AND STRENGTHS
`3
`140 mg capsules
`
`CONTRAINDICATIONS
`
`
`
`4
`None
`
`
`
`WARNINGS AND PRECAUTIONS
`5
`
`
`5.1 Hemorrhage
`Five percent of patients with MCL had Grade 3 or higher bleeding events (subdural hematoma,
`gastrointestinal bleeding, and hematuria). Overall, bleeding events including bruising of any
`grade occurred in 48% of patients with MCL treated with 560 mg daily.
`
`The mechanism for the bleeding events is not well understood.
`Consider the benefit-risk of ibrutinib in patients requiring antiplatelet or anticoagulant therapies.
`
`Consider the benefit-risk of withholding ibrutinib for at least 3 to 7 days pre and post-surgery
`depending upon the type of surgery and the risk of bleeding [see Clinical Studies (14.1)].
`
`
`
`5.2
`Infections
`
`Fatal and non-fatal infections have occurred with IMBRUVICA therapy. At least 25% of patients
`with MCL had infections Grade 3 or greater NCI Common Terminology Criteria for Adverse
`Events (CTCAE) [See Adverse Reactions (6)]. Monitor patients for fever and infections and
`evaluate promptly.
`
`Reference ID: 3395788
`
`3
`
`

`

`
`
`
` 5.3 Myelosuppression
`Treatment-emergent Grade 3 or 4 cytopenias were reported in 41% of patients. These included
`neutropenia (29%), thrombocytopenia (17%) and anemia (9%). Monitor complete blood counts
`monthly.
`
`5.4
`Renal Toxicity
`Fatal and serious cases of renal failure have occurred with IMBRUVICA therapy. Treatment-
`emergent increases in creatinine levels up to 1.5 times the upper limit of normal occurred in 67%
`of patients and from 1.5 to 3 times the upper limit of normal in 9% of patients. Periodically
`
`monitor creatinine levels. Maintain hydration.
`
`5.5
`Second Primary Malignancies
`
`Other malignancies (5%) have occurred in patients with MCL who have been treated with
`IMBRUVICA, including skin cancers (4%), and other carcinomas (1%).
`
`
`5.6
`Embryo-Fetal Toxicity
`Based on findings in animals, IMBRUVICA can cause fetal harm when administered to a
`pregnant woman. Ibrutinib caused malformations in rats at exposures 14 times those reported in
`patients with MCL receiving the ibrutinib dose of 560 mg per day. Reduced fetal weights were
`observed at lower exposures. Advise women to avoid becoming pregnant while taking
`IMBRUVICA. If this drug is used during pregnancy or if the patient becomes pregnant while
`taking this drug, the patient should be apprised of the potential hazard to a fetus [see Use in
`Specific Populations (8.1)].
`
`
`ADVERSE REACTIONS
`6
`
`The following adverse reactions are discussed in more detail in other sections of the labeling:
`
`• Hemorrhage [see Warnings and Precautions (5.1)]
`
`
`
`Infections [see Warnings and Precautions (5.2)]
`
`•
`
`• Myelosuppression [see Warnings and Precautions (5.3)]
`
`
`• Renal Toxicity [see Warnings and Precautions (5.4)]
`
`
`
`• Second Primary Malignancies [see Warnings and Precautions (5.5)]
`
`
`
`Because clinical trials are conducted under widely variable conditions, adverse event rates
`observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of
`another drug and may not reflect the rates observed in practice.
`The data described below reflect exposure to IMBRUVICA in a clinical trial that included
`111 patients with previously treated MCL treated with 560 mg daily with a median treatment
`duration of 8.3 months.
`
`Reference ID: 3395788
`
`4
`
`

`

`
`The most commonly occurring adverse reactions (≥ 20%) were thrombocytopenia, diarrhea,
`neutropenia, anemia, fatigue, musculoskeletal pain, peripheral edema, upper respiratory tract
`infection, nausea, bruising, dyspnea, constipation, rash, abdominal pain, vomiting and decreased
`appetite (See Tables 1 and 2).
`
`The most common Grade 3 or 4 non-hematological adverse reactions (≥ 5%) were pneumonia,
`abdominal pain, atrial fibrillation, diarrhea, fatigue, and skin infections.
`Adverse reactions from the MCL trial (N=111) using single agent IMBRUVICA 560 mg daily
`occurring at a rate of ≥ 10% are presented in Table 1.
`Table 1: Non-Hematologic Adverse Reactions in ≥ 10% of Patients with
`
`Mantle Cell Lymphoma (N=111)
`
`
`Preferred Term
`System Organ Class
`Gastrointestinal disorders Diarrhea
`Nausea
`Constipation
`Abdominal pain
`Vomiting
`Stomatitis
`Dyspepsia
`Infections and infestations Upper respiratory tract
`infection
`Urinary tract infection
`Pneumonia
`Skin infections
`Sinusitis
`Fatigue
`Peripheral edema
`
`Pyrexia
`Asthenia
`Bruising
`Rash
`Petechiae
`
`Musculoskeletal pain
`
`Muscle spasms
`Arthralgia
`
`Dyspnea
`
`Cough
`Epistaxis
`Decreased appetite
`
`Dehydration
`
`Dizziness
`
`Headache
`
`General disorders and
`administrative site
`conditions
`
`Skin and subcutaneous
`tissue disorders
`
`
`Musculoskeletal and
`
`connective tissue disorders
`
`Respiratory, thoracic and
`
`mediastinal disorders
`
`Metabolism and
`
`nutritional disorders
`
`Nervous system disorders
`
`All Grades (%)
`
`51
`
`31
`
`25
`
`24
`
`23
`
`17
`
`11
`
`34
`
`14
`
`14
`
`14
`
`13
`
`
`41
`35
`
`
`18
`14
`30
`
`25
`
`11
`
`
`37
`
`14
`11
`
`27
`
`19
`
`11
`
`21
`
`12
`
`14
`
`13
`
`Grade 3 or 4 (%)
`5
`0
`0
`5
`0
`1
`0
`
`0
`3
`7
`5
`1
`5
`3
`1
`3
`0
`3
`0
`1
`0
`0
`4
`0
`0
`2
`4
`0
`0
`
`5
`
`Reference ID: 3395788
`
`

`

`
`
` Table 2: Treatment-Emergent* Decrease of Hemoglobin, Platelets, or Neutrophils
`
`in Patients with MCL (N=111)
`
`
`
`Platelets Decreased
`
`Neutrophils Decreased
`
`Hemoglobin Decreased
`* Based on laboratory measurements and adverse reactions
`
`
`Percent of Patients (N=111)
`
`
`Grade 3 or 4 (%)
`All Grades (%)
`
`
`57
`17
`
`
`47
`29
`
`
`41
`9
`
`Ten patients (9%) discontinued treatment due to adverse reactions in the trial (N=111). The most
`frequent adverse reaction leading to treatment discontinuation was subdural hematoma (1.8%).
`Adverse reactions leading to dose reduction occurred in 14% of patients.
`Patients with MCL who develop lymphocytosis greater than 400,000/mcL have developed
`intracranial hemorrhage, lethargy, gait instability, and headache. However, some of these cases
`were in the setting of disease progression.
`Forty percent of patients had elevated uric acid levels on study including 13% with values above
`10 mg/dL. Adverse reaction of hyperuricemia was reported for 15% of patients.
`
`
`DRUG INTERACTIONS
`7
`
`Ibrutinib is primarily metabolized by cytochrome P450 enzyme 3A.
`
`7.1
`CYP3A Inhibitors
`In healthy volunteers, co-administration of ketoconazole, a strong CYP3A inhibitor, increased
`Cmax and AUC of ibrutinib by 29- and 24-fold, respectively. The highest ibrutinib dose evaluated
`
`in clinical trials was 12.5 mg/kg (actual doses of 840 – 1400 mg) given for 28 days with single
`dose AUC values of 1445 ± 869 ng ⋅ hr/mL which is approximately 50% greater than steady state
`exposures seen at the highest indicated dose (560 mg).
`Avoid concomitant administration of IMBRUVICA with strong or moderate inhibitors of
`CYP3A. For strong CYP3A inhibitors used short-term (e.g., antifungals and antibiotics for
`7 days or less, e.g., ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin,
`telithromycin) consider interrupting IMBRUVICA therapy during the duration of inhibitor use.
`Avoid strong CYP3A inhibitors that are needed chronically. If a moderate CYP3A inhibitor must
`be used, reduce the IMBRUVICA dose. Patients taking concomitant strong or moderate
` CYP3A4 inhibitors should be monitored more closely for signs of IMBRUVICA toxicity [see
`Dosage and Administration (2.4)].
`Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain moderate
`inhibitors of CYP3A [see Dosage and Administration (2.4), and Clinical Pharmacology (12.3)].
`
`
`
`Reference ID: 3395788
`
`6
`
`

`

`
`
`
`
` CYP3A Inducers
`
`7.2
` Administration of IMBRUVICA with strong inducers of CYP3A decrease ibrutinib plasma
`concentrations by approximately 10-fold.
`Avoid concomitant use of strong CYP3A inducers (e.g., carbamazepine, rifampin, phenytoin and
`St. John’s Wort). Consider alternative agents with less CYP3A induction [see Clinical
`Pharmacology (12.3)].
`
`
`USE IN SPECIFIC POPULATIONS
`8
`
`Pregnancy
`8.1
`Pregnancy Category D [see Warnings and Precautions (5.6)].
`
`Risk Summary
`Based on findings in animals, IMBRUVICA can cause fetal harm when administered to a
`pregnant woman. If IMBRUVICA is used during pregnancy or if the patient becomes pregnant
`while taking IMBRUVICA, the patient should be apprised of the potential hazard to the fetus.
`Animal Data
`Ibrutinib was administered orally to pregnant rats during the period of organogenesis at oral
`doses of 10, 40 and 80 mg/kg/day. Ibrutinib at a dose of 80 mg/kg/day was associated with
`visceral malformations (heart and major vessels) and increased post-implantation loss. The dose
`of 80 mg/kg/day in animals is approximately 14 times the exposure (AUC) in patients with MCL
`administered the dose of 560 mg daily. Ibrutinib at doses of 40 mg/kg/day or greater was
`associated with decreased fetal weights. The dose of 40 mg/kg/day in animals is approximately
`6 times the exposure (AUC) in patients with MCL administered the dose of 560 mg daily.
`
`8.3
`Nursing Mothers
`
`It is not known whether ibrutinib is excreted in human milk. Because many drugs are excreted in
`human milk and because of the potential for serious adverse reactions in nursing infants from
`
`IMBRUVICA, a decision should be made whether to discontinue nursing or to discontinue the
`drug, taking into account the importance of the drug to the mother.
`
`
`8.4
`Pediatric Use
`
`The safety and effectiveness of IMBRUVICA in pediatric patients has not been established.
`
`8.5 Geriatric Use
`Of the 111 patients treated for MCL, 63% were 65 years of age or older. No overall differences
`in effectiveness were observed between these patients and younger patients. Cardiac adverse
`events (atrial fibrillation and hypertension), infections (pneumonia and cellulitis) and
`gastrointestinal events (diarrhea and dehydration) occurred more frequently among elderly
`patients.
`
`
`Reference ID: 3395788
`
`7
`
`

`

`
`
`Renal Impairment
`8.6
`Less than 1% of ibrutinib is excreted renally. Ibrutinib exposure is not altered in patients with
`Creatinine clearance (CLcr) > 25 mL/min. There are no data in patients with severe renal
`impairment (CLcr < 25 mL/min) or patients on dialysis [see Clinical Pharmacology (12.3)].
`
`8.7 Hepatic Impairment
`Ibrutinib is metabolized in the liver and significant increases in exposure of ibrutinib are
`expected in patients with hepatic impairment. Patients with serum aspartate transaminase
`(AST/SGOT) or alanine transaminase (ALT/SGPT) ≥ 3.0 x upper limit of normal (ULN) were
`excluded from IMBRUVICA clinical trials. There is insufficient data to recommend a dose of
`IMBRUVICA in patients with baseline hepatic impairment [see Clinical Pharmacology (12.3)].
`8.8
`Females and Males of Reproductive Potential
`Advise women to avoid becoming pregnant while taking IMBRUVICA because IMBRUVICA
`
`can cause fetal harm [see Use in Specific Populations (8.1)].
`
`
`
`DESCRIPTION
`11
`Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK). It is a white to off-white solid with
`the empirical formula C25H24N6O2 and a molecular weight 440.50. Ibrutinib is freely soluble
`in dimethyl sulfoxide, soluble in methanol and practically insoluble in water.
`The chemical name for ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H­
`pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and has the following structure:
`
`O
`
`NH2
`
`N
`
`N
`
`N
`
`N
`
`(R)
`
`N
`
`O
`
`
`
`IMBRUVICA (ibrutinib) capsules for oral administration are supplied as white opaque capsules
`that contain 140 mg ibrutinib as the active ingredient. Each capsule also contains the following
`inactive ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose,
`sodium lauryl sulfate. The capsule shell contains gelatin, titanium dioxide and black ink. Each
`white opaque capsule is marked with “ibr 140 mg” in black ink.
`
`Reference ID: 3395788
`
`8
`
`

`

`
`
`CLINICAL PHARMACOLOGY
`12
`
`
` 12.1 Mechanism of Action
`Ibrutinib is a small-molecule inhibitor of BTK. Ibrutinib forms a covalent bond with a cysteine
`residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a
`signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s
`role in signaling through the B-cell surface receptors results in activation of pathways necessary
`for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits
`malignant B-cell proliferation and survival in vivo as well as cell migration and substrate
`adhesion in vitro.
`
`12.2 Pharmacodynamics
`In patients with recurrent B-cell lymphoma > 90% occupancy of the BTK active site in
`peripheral blood mononuclear cells was observed up to 24 hours after ibrutinib doses of
`
`≥ 2.5 mg/kg/day (≥ 175 mg/day for average weight of 70 kg).
`
`12.3 Pharmacokinetics
`Absorption
`Ibrutinib is absorbed after oral administration with a median Tmax of 1 to 2 hours. Ibrutinib
`
`exposure increases with doses up to 840 mg. The steady-state AUC observed in patients at
`560 mg is (mean ± standard deviation) 953 ± 705 ng⋅h/mL. Administration with food increases
`ibrutinib exposure approximately 2-fold compared with administration after overnight fasting.
`Distribution
`Reversible binding of ibrutinib to human plasma protein in vitro was 97.3% with no
`concentration dependence in the range of 50 to 1000 ng/mL. The apparent volume of distribution
`
` at steady state (Vd,ss/F) is approximately 10000 L.
`Metabolism
`Metabolism is the main route of elimination for ibrutinib. It is metabolized to several metabolites
`primarily by cytochrome P450, CYP3A, and to a minor extent by CYP2D6. The active
`metabolite, PCI-45227, is a dihydrodiol metabolite with inhibitory activity towards BTK
`approximately 15 times lower than that of ibrutinib. The range of the mean metabolite to parent
`ratio for PCI-45227 at steady-state is 1 to 2.8.
`
`Elimination
`Apparent clearance (CL/F) is approximately 1000 L/h. The half-life of ibrutinib is 4 to 6 hours.
`
`Ibrutinib, mainly in the form of metabolites, is eliminated primarily via feces. After a single oral
`administration of radiolabeled [14C]-ibrutinib in healthy subjects, approximately 90% of
`radioactivity was excreted within 168 hours, with the majority (80%) excreted in the feces and
`less than 10% accounted for in urine. Unchanged ibrutinib accounted for approximately 1% of
`
`Reference ID: 3395788
`
`9
`
`

`

`
`the radiolabeled excretion product in feces and none in urine, with the remainder of the dose
`being metabolites.
`Age
`Age (37 to 84 years) does not alter ibrutinib systemic clearance.
`Gender
`Gender does not alter ibrutinib systemic clearance.
`Renal Impairment
`Ibrutinib is not significantly cleared renally; urinary excretion of metabolites is < 10% of the
`dose. Creatinine clearance > 25 mL/min had no influence on the exposure to IMBRUVICA.
`There are no data in patients with severe renal impairment (CLcr < 25 mL/min) or in patients on
`dialysis.
`Hepatic Impairment
`Ibrutinib is metabolized in the liver. No clinical trials have been completed in subjects with
`impaired hepatic function. Preliminary PK data from an ongoing trial in subjects with hepatic
`impairment indicate that ibrutinib exposure is approximately 6-fold higher in subjects (N=3) with
`moderate hepatic impairment (Child-Pugh B) compared with mean exposures observed in
`healthy volunteer trials.
`
`Drug Interactions
`
`Coadministration of Ibrutinib with CYP3A Inhibitors
`In a sequential design trial of 18 healthy volunteers, a single dose of 120 mg of IMBRUVICA
`was administered alone on Day 1 and a single dose of 40 mg of IMBRUVICA was administered
`on Day 7 in combination with 400 mg of ketoconazole (given daily on Days 4 - 9). Ketoconazole
`increased ibrutinib dose-normalized Cmax and AUC 29-fold and 24-fold, respectively.
`Simulations using physiologically-based pharmacokinetic (PBPK) models suggested that
`moderate CYP3A inhibitors (diltiazem and erythromycin) may increase the AUC of ibrutinib
`6 to 9-fold in fasted condition.
`Coadministration of Ibrutinib with CYP3A Inducers
`Preliminary PK data from an ongoing dedicated drug interaction trial and simulations using
`PBPK indicate that rifampin (a strong CYP3A inducer) can decrease ibrutinib Cmax and AUC by
`more than 10-fold. Simulations using PBPK suggested that a moderate CYP3A inducer
`(efavirenz) may decrease the AUC of ibrutinib up to 3-fold.
`Coadministration of Ibrutinib with CYP Substrates
`
`
`In vitro studies indicated that ibrutinib (I/Ki < 0.07 using mean Cmax at 560 mg) and PCI-45227
`(I/Ki < 0.03) are unlikely to be inhibitors of any major CYPs at clinical doses. Both ibrutinib and
`the PCI-45227 are weak inducers of CYP450 isoenzymes in vitro.
`
`Reference ID: 3395788
`
`
`
` 10
`
`

`

`
`Coadministration of Ibrutinib with Substrates of Transporters
`
`In vitro studies indicated that ibrutinib is not a substrate of p-glycoprotein (P-gp). Systemic
`ibrutinib is unlikely to be an inhibitor of P-gp at clinical doses ([I]1/Ki < 0.1). However, it may
`have an effect on P-gp substrates in the GI tract due to higher local concentrations after an oral
`dose. Co-administration of oral narrow therapeutic index P-gp substrates (e.g., digoxin) with
`IMBRUVICA may increase their blood concentration.
`
`
`NONCLINICAL TOXICOLOGY
`13
`
`13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
`
`Carcinogenicity studies have not been conducted with ibrutinib.
`Ibrutinib was not mutagenic in a bacterial mutagenicity (Ames) assay, was not clastogenic in a
`chromosome aberration assay in mammalian (CHO) cells, nor was it clastogenic in an in vivo
`bone marrow micronucleus assay in mice at doses up to 2000 mg/kg.
`Fertility studies with ibrutinib have not been conducted in animals. In the general toxicology
`studies conducted in rats and dogs, orally administered ibrutinib did not result in adverse effects
`on reproductive organs.
`
`
`CLINICAL STUDIES
`14
`
`14.1 Mantle Cell Lymphoma
`The safety and efficacy of IMBRUVICA in patients with MCL who have received at least one
`prior therapy were evaluated in an open-label, multi-center, single-arm trial of 111 previously
`treated patients. The median age was 68 years (range, 40 to 84 years), 77% were male, and 92%
`were Caucasian. At baseline, 89% of patients had a baseline ECOG performance status of 0 or 1.
`The median time since diagnosis was 42 months, and median number of prior treatments was 3
`(range, 1 to 5 treatments), including 11% with prior stem cell transplant. At baseline, 39% of
`subjects had at least one tumor ≥ 5 cm, 49% had bone marrow involvement, and 54% had
`extranodal involvement at screening.
`IMBRUVICA was administered orally at 560 mg once daily until disease progression or
`unacceptable toxicity. Tumor response was assessed according to the revised International
`Working Group (IWG) for non-Hodgkin’s lymphoma (NHL) criteria. The primary endpoint in
`this study was investigator-assessed overall response rate (ORR). Responses to IMBRUVICA
`are shown in Table 3.
`
`
`
`
`Reference ID: 3395788
`
`
`
` 11
`
`

`

`
`
`Table 3: Overall Response Rate (ORR) and Duration of Response (DOR) Based on
`
`Investigator Assessment in Patients with Mantle Cell Lymphoma
`
`
`Total (N=111)
`
`
`65.8
`ORR (%)
`
`
`(56.2, 74.5)
`95% CI (%)
`
`17.1
`CR (%)
`
`48.6
`PR (%)
`17.5 (15.8, NR)
`Median DOR months 95% CI
`CI = confidence interval; CR = complete response; PR = partial response; NR = not reached
`
`An Independent Review Committee (IRC) performed independent reading and interpretation of
`imaging scans. The IRC review demonstrated an ORR of 69%.
`The median time to response was 1.9 months.
`Lymphocytosis
`Upon initiation of IMBRUVICA, a temporary increase in lymphocyte counts (i.e., ≥ 50%
`
`increase from baseline and above absolute lymphocyte count of 5,000/mcL) occurred in 33% of
`patients in the MCL study. The onset of isolated lymphocytosis occurs during the first few weeks
`(median time 1.1 weeks) of IMBRUVICA therapy and resolves by a median of 8 weeks.
`
`
`HOW SUPPLIED/STORAGE AND HANDLING
`16
`The white opaque 140 mg capsules marked with “ibr 140 mg” in black ink are available in white
`HDPE bottles with a child-resistant closure:
`
`• 90 capsules per bottle: NDC 57962-140-09
`
`• 120 capsules per bottle: NDC 57962-140-12
`
`Store bottles at room temperature 20°C to 25°C (68°F to 77°F). Excursions are permitted
`between 15°C and 30°C (59°F to 86°F). Retain in original package.
`
`
`PATIENT COUNSELING INFORMATION
`17
`See FDA-approved patient labeling (Patient Information)
`• Hemorrhage:
`
`
`Inform patients of the possibility of bleeding, and to report any signs or symptoms (blood in
`stools or urine, prolonged or uncontrolled bleeding). Inform the patient that IMBRUVICA
`may need to be interrupted for medical or dental procedures [see Warnings and Precautions
`(5.1)].
`Infections:
`
`Inform patients of the possibility of serious infection, and to report any signs or symptoms
`
`(fever, chills) suggestive of infection [see Warnings and Precautions (5.2)].
`
`•
`
`
`
`
` 12
`
`Reference ID: 3395788
`
`

`

`•
`
`
`
`• Renal toxicity:
`
`Inform patients of the possibility of renal toxicity. Advise patients to maintain adequate
`hydration [see Warnings and Precautions (5.4)].
`• Second primary malignancies:
`
`Inform patients that other malignancies have occurred in patients with MCL who have been
`treated with IMBRUVICA, including skin cancers and other carcinomas [see Warnings and
`Precautions (5.5)].
`• Embryo-fetal toxicity:
`
`
`Advise women of the potential hazard to a fetus and to avoid becoming pregnant [see
`
`Warnings and Precautions (5.6)].
`Inform patients to take IMBRUVICA orally once daily according to their physician’s
`instructions and that the capsules should be swallowed whole with a glass of water without
`being opened, broken, or chewed at approximately the same time each day [see Dosage and
`Administration (2.1)].
`• Advise patients that in the event of a missed daily dose of IMBRUVICA, it should be taken
`
`as soon as possible on the same day with a return to the normal schedule the following day.
`Patients should not take extra capsules to make up the missed dose [see Dosage and
`Administration (2.5)].
`• Advise patients of the common side effects associated with IMBRUVICA [see Adverse
`
`Reactions (6)]. Direct the patient to a complete list of adverse drug reactions in PATIENT
`INFORMATION.
`• Advise patients to inform their health care providers of all concomitant medications,
`
`including prescription medicines, over-the-counter drugs, vitamins, and herbal products
`[see Drug Interactions (7)].
`• Advise patients that they may experience loose stools or diarrhea, and should contact their
`
`doctor if their diarrhea persists.
`
`
`Active ingredient made in China.
`
`
`Distributed and Marketed by:
`
`Pharmacyclics, Inc.
`
`
`Sunnyvale, CA USA 94085
`
`and
`
`Marketed by:
`
`Janssen Biotech, Inc.
`
`Horsham, PA USA 19044
`
`
`
`Patent http://www.imbruvica.com
`
`
`IMBRUVICA™ is a trademark owned by Pharmacyclics, Inc.
`
`
`
`©Pharmacyclics, Inc. 2013
`
`Issued: November 2013
`
`
`Reference ID: 3395788
`
`
`
` 13
`
`

`

` Patient Information
`
` IMBRUVICA (im-BRU-vih-kuh)
`(ibrutinib) capsules
`
`
`
`What is IMBRUVICA?
`
`IMBRUVICA is a prescription medicine used to treat people with mantle cell lymphoma (MCL) who have
`
`received at least one prior treatment.
`
`It is not known if IMBRUVICA is safe and effective in children.
`
`What should I tell my healthcare provider before taking IMBRUVICA?
`
`Before you take IMBRUVICA, tell your healthcare provider about all of your medical
`
`
`conditions, including if you:
`
`• have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA for
`
`
`any planned medical, surgical, or dental procedure.
`• have bleeding problems
`
`• have liver problems
`
`
`• are pregnant or plan to become pregnant. IMBRUVICA can harm your unborn baby. You should not
`
`
`become pregnant while taking IMBRUVICA.
`
`• are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will
`
`take IMBRUVICA or breastfeed. You should not do both.
`Tell your healthcare provider about all the medicines you take, including prescription and over­
`the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA with certain other
`medicines may affect how IMBRUVICA works and can cause side effects.
`How should I take IMBRUVICA?
`• Take IMBRUVICA exactly as your healthcare provider tells you to take it.
`
`• Take IMBRUVICA 1 time a day.
`
`• Swallow IMBRUVICA capsules whole with a glass of water. Do not open, break, or chew IMBRUVICA
`
`capsules.
`• Take IMBRUVICA at about the same time each day.
`
`
`• If you miss a dose of IMBRUVICA take it as soon as you remember on the same day. Take your next
`
`
`dose of IMBRUVICA at your regular time on the next day. Do not take 2 doses of IMBRUVICA on the
`
`
`
`same day to make up for a missed dose.
`What should I avoid while taking IMBRUVICA?
`
`● You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in
`
`
`
`
`marmalades) while you are taking IMBRUVICA. These products may increase the amount of
`
`
`IMBRUVICA in your blood.
`What are the possible side effects of IMBRUVICA?
`
`IMBRUVICA may cause serious side effects, including:
`• Bleedi

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket